Andrew Hill Investment Advisors Inc. Acquires New Stake in Eli Lilly and Company (NYSE:LLY)

Andrew Hill Investment Advisors Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,894 shares of the company’s stock, valued at approximately $1,105,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lipe & Dalton bought a new position in shares of Eli Lilly and Company in the 4th quarter worth $26,000. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at about $27,000. Retirement Group LLC grew its stake in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the last quarter. Cornerstone Planning Group LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $33,000. Finally, Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter worth about $35,000. 82.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $17.42 on Friday, hitting $728.53. The stock had a trading volume of 1,545,573 shares, compared to its average volume of 3,047,175. The company’s 50 day moving average price is $764.24 and its 200 day moving average price is $658.28. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a market cap of $692.22 billion, a price-to-earnings ratio of 125.67, a P/E/G ratio of 1.64 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $369.76 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the prior year, the business earned $2.09 EPS. The firm’s revenue was up 28.1% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on LLY shares. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday. Citigroup increased their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.